News

A training program in which patients walk while listening to regular beats can improve the velocity and cadence of Parkinson’s disease patients, while reducing their risk of falling, a study shows. The study, “Rhythmic auditory stimulation for reduction of falls in Parkinson’s disease: a randomized controlled study,” was published…

Machine learning identifies individuals with reduced odor and taste sensitivity as people at risk for developing Parkinson’s disease, researchers from Italy report. The approach could be part of a noninvasive method to study early-onset Parkinson’s, the findings suggest. The study, “Comparative Motor Pre-clinical Assessment in Parkinson’s…

The traditional Chinese compound Zishenpingchan can be used as an add-on treatment to levodopa for improvements in motor symptoms and quality of life in patients with Parkinson’s disease, according to researchers. The study, “Zishenpingchan granules for the treatment of Parkinson’s disease: a randomized, double-blind, placebo-controlled clinical trial,” was…

A type of immune cell called Th17 may be a key a promoter of neurodegeneration in Parkinson’s disease by producing the pro-inflammatory molecule interleukin-17 (IL-17), according to a study. Researchers also found that the common anti-inflammatory medication Cosentyx (secukinumab), an antibody against IL-17, seems to prevent this mechanism and the…

How cell surface proteins participate in spreading, from one cell to another, misfolded proteins related to neurodegenerative diseases like Parkinson’s and Alzheimer’s, possibly aiding in the progression of these disorders, was seen in early research. The study, “Specific glycosaminoglycan chain length and sulfation patterns are required for cell…

A Phase 1 trial will test the potential of ketamine — an analgesic medicine used for depression and pain — at reducing the uncontrollable, jerky movements that arise in Parkinson’s disease patients after long-term treatment with levopoda. Levodopa, probably the most common treatment for Parkinson’s disease, is effective at improving the stiffness…

An anticonvulsant medication called methsuximide may be a new approach for treating a neurodegenerative diseases that include Parkinson’s, because it shows a potential to be neuroprotective at low doses, early research reports. Specifically, this epilepsy treatment’s active molecule — α-methyl-α-phenylsuccinimide — eased movement difficulties, extended lifespans, and showed itself to…

Voyager Therapeutics announced likely plans to request approval of VY-AADC as a Parkinson’s gene therapy, based on feedback it received from the U.S. Food and Drug Administration (FDA) and eventual outcomes of a newly opened Phase 2 trial. The company also reported that its Phase 1 trial of VY-AADC showed improvements in patients’ motor…

Neuraly announced it has raised $36 million to advance its lead candidate NLY01 into clinical testing as a potential disease-modifying agent for Parkinson’s disease, and to develop other investigative compounds for this and similar neurodegenerative disorders. The company, a Johns Hopkins University startup, expects to start a clinical trial of NLY01…

A new chemical probe that binds to a protein called DJ-1 — a sensor of oxidative stress and a potential biomarker of Parkinson’s disease — may help researchers understand how the protein participates in disease progression, a study suggests. The study, “A chemical probe to monitor the parkinsonism-…